12- and 18-Month Outcomes and Long- Term Survival of Tofacitinib in Ulcerative Colitis

Study identification

• EU PAS number:
  EUPAS44985
• Study ID:
  50427
• Official title and acronym:
  12- and 18-Month Outcomes and Long- Term Survival of Tofacitinib in Ulcerative Colitis
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  Outcomes and Long-Term Survival of Tofacitinib in patients with Ulcerative Colitis
• Study status:
  Finalised

Research institutions and networks

Institutions

Pfizer

Networks

Mass General Brigham (MGB)

Study timelines

Date when funding contract was signed

Planned: 30/11/2021

Actual: 06/12/2021

Study start date

Planned: 01/03/2022

Actual: 24/02/2022

Date of final study report

Planned: 30/03/2023

Actual: 20/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable